PlainMeds provides educational information only. This is not medical advice. Always consult your doctor or pharmacist.

Drug side effects

labetalol Side Effects

The reactions most often reported to the FDA for labetalol (also sold as Trandate), with demographics, serious outcomes, and reporting trends.

Data updated 2026-05-15

12,726
FAERS reports

Data from the FDA Adverse Event Reporting System (FAERS), 2004 to 2025. A FAERS report records a temporal association, not proof of cause. See our methodology for how figures are compiled and de-duplicated.

The most commonly reported side effects of labetalol come from 12,726 reports to the FDA, broken down here by frequency, patient demographics, and serious outcomes.

This page analyzes 12,726 reports to the FDA Adverse Event Reporting System (FAERS) for labetalol (Trandate): the reactions reported most often, who reported them, serious outcomes such as hospitalization, and year-over-year trends. A FAERS report does not prove the drug caused the effect, and report volume tracks how widely a drug is used, not how likely an effect is for any one person. Educational information, not medical advice.

Total Reports

12,726

Reports Mentioning Death

1,314

10.3% of reports — not proof the medicine caused the death

Hospitalizations

4,839

38.0% of reports

Top Indication

Product Used For Unknown Indication

Most Reported Adverse Reactions

FOETAL EXPOSURE DURING PREGNANCY
931
MATERNAL EXPOSURE DURING PREGNANCY
912
HYPERTENSION
721
PREMATURE BABY
716
CHRONIC KIDNEY DISEASE
645
ACUTE KIDNEY INJURY
623
EXPOSURE DURING PREGNANCY
622
FATIGUE
587
RENAL FAILURE
576
NAUSEA
509
PREMATURE DELIVERY
491
HEADACHE
484
DYSPNOEA
478
DIARRHOEA
457
PAIN
429
LOW BIRTH WEIGHT BABY
399
END STAGE RENAL DISEASE
381
DEATH
372

Who Reports Side Effects

Gender Distribution

Female 7,289 (64%)
Male 4,115 (36%)
Unknown 31

Age Distribution

0-17 559 (7%)
18-44 2,615 (31%)
45-64 2,281 (27%)
65-74 1,540 (18%)
75+ 1,502 (18%)

Reporting Trend by Year

2004 2025

Reactions in Death Reports

Top reactions reported in 1,314 reports where death was an outcome. These are voluntarily reported and do not establish causation.

Reaction Reports
DEATH 371
COMPLETED SUICIDE 165
FOETAL EXPOSURE DURING PREGNANCY 118
RENAL FAILURE 110
CARDIAC ARREST 103
ACUTE KIDNEY INJURY 96
CHRONIC KIDNEY DISEASE 92
END STAGE RENAL DISEASE 72
TOXICITY TO VARIOUS AGENTS 53
HYPOTENSION 52
PNEUMONIA 50
RESPIRATORY FAILURE 50
ALANINE AMINOTRANSFERASE INCREASED 42
CEREBROVASCULAR ACCIDENT 42
DYSPNOEA 42
ASPARTATE AMINOTRANSFERASE INCREASED 41
HYDROPS FOETALIS 41
PAIN 40
CLEFT LIP AND PALATE 39

Reactions in Hospitalization Reports

Top reactions in 4,839 reports where hospitalization was an outcome.

Reaction Reports
HYPERTENSION 440
ACUTE KIDNEY INJURY 346
MATERNAL EXPOSURE DURING PREGNANCY 316
RENAL FAILURE 275
DYSPNOEA 251
FOETAL EXPOSURE DURING PREGNANCY 236
HYPOTENSION 230
CHRONIC KIDNEY DISEASE 224
PNEUMONIA 222
EXPOSURE DURING PREGNANCY 204
NAUSEA 203
FATIGUE 192
PREMATURE BABY 174
VOMITING 174
FALL 173
HEADACHE 173
PAIN 169
ASTHENIA 167

Compare labetalol vs acebutolol →

What the FAERS Data Reveals About labetalol Side Effects

The FDA Adverse Event Reporting System (FAERS) contains 12,726 voluntary reports linked to labetalol and its brand equivalents (Trandate), spanning 2004 through 2025. Of those, 1,314 (10.3%) listed death as an outcome and 4,839 (38.0%) involved hospitalization. The most common indication reported alongside adverse events was Product Used For Unknown Indication.

Demographic breakdowns help contextualize who is being exposed to the drug. Of reports with known sex, 64% were female and 36% male; age distribution skews toward 18-44, with 2,615 reports in that bracket. The single most reported reaction is foetal exposure during pregnancy with 931 submissions, followed by maternal exposure during pregnancy and hypertension.

How to read these numbers

FAERS is a signal-detection tool, not a scorecard. Reports are voluntary, and a single case may list multiple suspect drugs, so numbers above should not be read as incidence rates or per-patient risk. Widely prescribed drugs naturally accumulate more reports than niche therapies even when individual risk is low. These aggregates are useful for spotting patterns that merit further pharmacovigilance, not for choosing between medications. This page is for educational reference only and is not medical advice, speak with a licensed clinician about any side-effect concerns.